These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 27540978

  • 41. Genomic heterogeneity of osteosarcoma - shift from single candidates to functional modules.
    Poos K, Smida J, Maugg D, Eckstein G, Baumhoer D, Nathrath M, Korsching E.
    PLoS One; 2015; 10(4):e0123082. PubMed ID: 25848766
    [Abstract] [Full Text] [Related]

  • 42. Has-mir-146a rs2910164 polymorphism and risk of immune thrombocytopenia.
    Zhao H, Zhang Y, Xue F, Xu J, Fang Z.
    Autoimmunity; 2014 May; 47(3):173-6. PubMed ID: 24502829
    [Abstract] [Full Text] [Related]

  • 43. MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma.
    Xu SH, Yang YL, Han SM, Wu ZH.
    World J Surg Oncol; 2014 Jun 27; 12():195. PubMed ID: 24969351
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Association between genetic variants in pre-microRNAs and survival of early-stage NSCLC.
    Hong MJ, Choi YY, Jang JA, Jung HJ, Lee SY, Lee WK, Yoo SS, Lee J, Cha SI, Kim CH, Lee E, Jeon HS, Son JW, Park JY.
    J Thorac Oncol; 2013 Jun 27; 8(6):703-10. PubMed ID: 23470291
    [Abstract] [Full Text] [Related]

  • 46. Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.
    Yang J, Wang ZG, Cai HQ, Li YC, Xu YL.
    Asian Pac J Cancer Prev; 2013 Jun 27; 14(8):4595-8. PubMed ID: 24083708
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy.
    Zhang SL, Mao NF, Sun JY, Shi ZC, Wang B, Sun YJ.
    Asian Pac J Cancer Prev; 2012 Jun 27; 13(6):2705-9. PubMed ID: 22938445
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
    Liu JY, Zhu BR, Wang YD, Sun X.
    Int J Clin Oncol; 2020 Jun 27; 25(6):1195-1205. PubMed ID: 32215805
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.
    Huang X, Yang Y, Guo Y, Cao ZL, Cui ZW, Hu TC, Gao LB.
    Genet Mol Res; 2015 Dec 14; 14(4):16913-20. PubMed ID: 26681038
    [Abstract] [Full Text] [Related]

  • 58. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma.
    Ma W, Zhang X, Chai J, Chen P, Ren P, Gong M.
    Tumour Biol; 2014 Dec 14; 35(12):12467-72. PubMed ID: 25185654
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.